Does Verastem Oncology’s updated RAMP 201 dataset change the outlook for low-grade serous ovarian cancer treatment?
Verastem Oncology’s two-year ovarian cancer data strengthen the case for avutometinib plus defactinib. Read what this means next.
Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.